Featuring perspectives from 36 clinical investigators. Published April 2025.
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Audio Program: Research To Practice designates this enduring material for a maximum of 15.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Video Program: Research To Practice designates this enduring material for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 15.75 (audio) and 15.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.
AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/GMO25/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/GMO25/Video.
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/GMO25/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/GMO25.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Thomas A Abrams, MD
Institute Physician
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Director, Liver Tumor Center
Boston, Massachusetts
Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, HistoSonics; Consulting Agreements: Elevar Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP.
Rahul Aggarwal, MD
Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
Director, Genitourinary Medical Oncology
University of California, San Francisco
Department of Medicine
Division of Hematology/Oncology
Associate Director for Clinical Research
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Advisory Committees: Novartis; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, FibroGen Inc, Flare Therapeutics, Johnson & Johnson Pharmaceuticals, Merck, ORIC Pharmaceuticals, Pfizer Inc, Xencor; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Merck; Nonrelevant Financial Relationships: Prostate Cancer Clinical Trials Consortium.
Aditya Bardia, MD, MPH
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California
Consulting Agreements and Contracted Research: Alyssum Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi.
Mitesh J Borad, MD
Professor of Medicine
Mayo Clinic College of Medicine and Science
Getz Family Professor of Research
Mayo Clinic Arizona
Program Leader, Novel Therapeutics and Therapeutic Modalities Program
Mayo Clinic Comprehensive Cancer Center
Phoenix, Arizona
Advisory Committees: Elevar Therapeutics; Consulting Agreements: Guardant Health, Jazz Pharmaceuticals Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Biond Biologics, Dragonfly Therapeutics, Eisai Inc, Elevation Oncology, Incyte Corporation, Kinnate Biopharma, Nuvectis Pharma Inc, Pfizer Inc, Relay Therapeutics, Revolution Medicines, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC; Data and Safety Monitoring Boards/Committees: Accession Therapeutics.
Virginia F Borges, MD, MMSc
Professor of Medicine with Tenure
Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research
Deputy Head, Division of Medical Oncology
Director, Breast Cancer Research Program and Young Women’s Breast Cancer Translational Program
University of Colorado Cancer Center
Aurora, Colorado
Advisory Committees: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Consulting Agreements: Gilead Sciences Inc, Olema Oncology; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: Pfizer Inc, Seagen Inc (HER2CLIMB-02 trial); Nonrelevant Financial Relationships: Pearl Scientific LLC.
Prithviraj Bose, MD
Professor, Department of Leukemia
Co-Leader, Section of Myeloproliferative Neoplasms
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committees: Blueprint Medicines, Geron Corporation, GSK, Karyopharm Therapeutics, Keros Therapeutics, PharmaEssentia, Sumitomo Dainippon Pharma Oncology Inc; Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Jubilant Pharma Limited, Karyopharm Therapeutics, Keros Therapeutics, Morphic Therapeutic, MorphoSys, Novartis, Ono Pharmaceutical Co Ltd, PharmaEssentia, RayThera, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Ajax Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Sumitomo Dainippon Pharma Oncology Inc, Telios Pharma Inc.
Harold J Burstein, MD, PhD
Institute Physician
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
No relevant conflicts of interest to disclose.
Natalie S Callander, MD
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
No relevant conflicts of interest to disclose.
Rashmi Chugh, MD
Professor of Internal Medicine
Division of Hematology/Oncology
Rogel Comprehensive Cancer Center
University of Michigan
Ann Arbor, Michigan
Advisory Committees: Deciphera Pharmaceuticals Inc, Inhibrx, Recordati, SpringWorks Therapeutics Inc.
Christopher Flowers, MD, MS
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.
Jonathan Goldman, MD
Associate Professor, UCLA Hematology and Oncology
Director of Clinical Trials in Thoracic Oncology
UCLA Health
Santa Monica, California
Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Gritstone bio, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Advaxis Inc,AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, Spectrum Pharmaceuticals Inc, Vaccinex Inc.
Ramaswamy Govindan, MD
Professor of Medicine
Director, Section of Oncology
Anheuser-Busch Endowed Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri
No relevant conflicts of interest to disclose.
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Director, Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio
Consulting Agreements: Astellas, Bristol Myers Squibb, Gilead Sciences Inc, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Acrivon Therapeutics, Bristol Myers Squibb, Convergent Therapeutics Inc, Flare Therapeutics, Merck, Novartis, Roche Laboratories Inc, Tyra Biosciences Inc; Data and Safety Monitoring Boards/Committees: Protara Therapeutics; Speakers Bureaus: Bristol Myers Squibb; Stock Options/Stock — Public Companies: BioNTech SE, Nektar Therapeutics.
Yelena Y Janjigian, MD
Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Advisory Committees: AbbVie Inc, AmerisourceBergen, Arcus Biosciences, ARS Pharmaceuticals, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, eChinaHealth, Eisai Inc, Geneos Therapeutics, GSK, Guardant Health, HC Wainwright & Co, Imugene, Inspirna, Lilly, Lynx Health, Merck, Merck Serono, Mersana Therapeutics Inc, PeerMD, Pfizer Inc, Sanofi, Seagen Inc, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co Ltd, Zymeworks Inc; Contracted Research: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Inspirna, Lilly, Merck, Transcenta; Stock Options — Private Companies: Inspirna; Nonrelevant Financial Relationships: Clinical Care Options, Cycle for Survival, ED Medresources Inc, Fred’s Team, Imedex, Master Clinician Alliance, MJH Life Sciences, National Cancer Institute, Paradigm Medical Communications, PeerView Institute, Physician Education Resource (PER), Stand Up 2 Cancer, Talem Health, TotalCME, US Department of Defense, Veda Life Sciences Inc (stock options), WebMD.
Ahmed Omar Kaseb, MD, CMQ
John E and Dorothy J Harris Professor in Gastrointestinal Cancer Research
Member, National Hepatobiliary Task Force, NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma Program
Director, MD Anderson HCC SPORE
Editor-in-Chief, Journal of Hepatocellular Carcinoma
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committees, Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc.
Samuel J Klempner, MD
Associate Professor
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts
Advisory Committees: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, Gilead Sciences Inc, I-Mab Biopharma, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Taiho Oncology Inc; Consulting Agreements: Astellas, Novartis (ended 2023); Stock Options — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie's Dream Foundation, Degregorio Family Foundation, Gastric Cancer Foundation, Gateway for Cancer Research, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation.
Andrew T Kuykendall, MD
Associate Member, Department of Malignant Hematology
Moffitt Cancer Center
Associate Professor, Department of Oncologic Sciences
University of South Florida
Tampa, Florida
Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, Protagonist Therapeutics, MorphoSys; Data and Safety MonitoringBoard/Committees: Geron Corporation.
Nicole Lamanna, MD
Judy Horrigan Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Leukemia Service, Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Irving Medical Center
New York, New York
Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd,Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research (Institutional Research/Grant Support): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, Octapharma, Oncternal Therapeutics; Honoraria: AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Curio Science, DAVA Oncology, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Nonrelevant Financial Relationships: Bio Ascend, Clinical Care Options, OncLive, PeerView, Physician Education Resource (PER), Targeted Oncology.
Natasha B Leighl, MD, MMSc (Clin Epi)
Professor, Department of Medicine
Adjunct Professor, IHPME, Dalla Lana School of Public Health
University of Toronto
OSI Pharmaceuticals Foundation Chair in New Cancer Drug Development
Thoracic Oncology Lead, Division of Medical Oncology
Princess Margaret Cancer Center
Toronto, Ontario, Canada
No relevant conflicts of interest to disclose.
Christopher Lieu, MD
Professor of Medicine
Associate Director for Clinical Research
Co-Director, GI Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado
Consulting Agreements: Amgen Inc, Pfizer Inc; Contracted Research: Genentech, a member of the Roche Group, Sanofi.
Stephen V Liu, MD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC
Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc,Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals; Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Guardant Health, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Merus, Mirati Therapeutics Inc, Natera Inc, Novartis, OSE Immunotherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc, Yuhan Corporation; Contracted Research: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Cogent Biosciences, Duality Biologics, Elevation Oncology, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma Biotechnology Inc, RAPT Therapeutics, Synthekine, SystImmune Inc.
Amit Mahipal, MD, MPH
Professor
Case Western Reserve University
Director, GI Oncology
UH Seidman Cancer Center
Cleveland, Ohio
No relevant conflicts of interest to disclose.
Thomas Martin, MD
Associate Chief, Hematology/Oncology
Director, Hematology, Blood and Marrow Transplantation and Cell Therapy
Helen Diller Family Comprehensive Cancer Center
UCSF Medical Center
San Francisco, California
Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson Pharmaceuticals, Sanofi; Data and Safety MonitoringBoards/Committees: Lilly.
Paul E Oberstein, MD, MS
Associate Professor of Medicine
Section Chief, Gastrointestinal Medical Oncology
Co-Director, Pancreatic Disease Center
Perlmutter Comprehensive Cancer Center
New York, New York
Advisory Committees: Boehringer Ingelheim Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck; Consulting Agreements: Ipsen Biopharmaceuticals Inc; Speakers Bureaus: Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc.
William K Oh, MD
Director of Precision Medicine
Yale Cancer Center
Professor of Medicine, Division of Medical Oncology
Yale School of Medicine
Medical Director, Service Line
Smilow Cancer Hospital at Greenwich Hospital
New Haven, Connecticut
Advisory Committees: Pfizer Inc; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Cytogen Corporation, Nature's Toolbox Inc, Novartis, Sumitomo Dainippon Pharma Oncology Inc; Stock Options — Private Companies: Nature’s Toolbox Inc; Stock Options/Stock —Public Companies: GeneDx.
David M O'Malley, MD
Director and Professor
Division of Gynecologic Oncology in Obstetrics and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and The James Comprehensive Cancer Center
Columbus, Ohio
Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Genmab US Inc, GSK, Merck, MSD, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG.
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas
Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC.
Krish Patel, MD
Director of Lymphoma Research
Sarah Cannon Research Institute
Nashville, Tennessee
Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Lilly, Merck, Nurix Therapeutics Inc, Pfizer Inc; Contracted Research (Funding to Institution): AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Century Therapeutics, CRISPR Therapeutics, Fate Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Lilly, Merck, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sana, Xencor.
Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Henry Ford Cancer Institute
Wayne State University
Detroit, Michigan
Advisory Committees: Agenus Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Gilead Sciences Inc, HUYA Bioscience International, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Pfizer Inc, Processa Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen, BioNTech SE, Moderna, Novocure Inc; Data and Safety Monitoring Boards/Committees: Cyclacel Pharmaceuticals Inc, Oncolytics Biotech Inc; Speakers Bureaus: Astellas, Incyte Corporation.
Kanwal Raghav, MD
Associate Professor, Gastrointestinal Medical Oncology
Executive Medical Director (EMD), Ambulatory Treatment Centers
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committees and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP,Daiichi Sankyo Inc, Eisai Inc, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Pfizer Inc.
Richard F Riedel, MD
Professor of Medicine with Tenure
Associate Director, Clinical and Translational Research
Duke Sarcoma Center
Duke Cancer Institute
Duke University
Durham, North Carolina
Advisory Committees and Consulting Agreements: Aadi Bioscience,Adaptimmune, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, GSK, NanoCarrier Co Ltd, Recordati, SpringWorks Therapeutics Inc; Contracted Research: Aadi Bioscience, Adaptimmune, Arog Pharmaceuticals Inc, Ayala Pharmaceuticals, BioAtla, Blueprint Medicines, Cogent Biosciences, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, GSK, Inhibrx, Intensity Therapeutics, NanoCarrier Co Ltd, Oncternal Therapeutics, PTC Therapeutics, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, TRACON Pharmaceuticals Inc, Trillium Therapeutics Inc; Nonrelevant Financial Relationships: SARC (Sarcoma Alliance for Research through Collaboration).
Kerry A Rogers, MD
Associate Professor
Division of Hematology
The Ohio State University
Columbus, Ohio
Advisory Committees: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, Alpine Immune Sciences, BeiGene Ltd, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis.
Jonathan E Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W Ercklentz Chair
Memorial Sloan Kettering Cancer Center
New York, New York
Advisory Committees: Astellas, Seagen Inc, Tyra Biosciences Inc; Consulting Agreements: Aadi Bioscience, Aktis Oncology, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Generate Biomedicines, Gilead Sciences Inc, Hengrui Therapeutics Inc, Imvax Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc, Samsung Bioepis, Seagen Inc, Tyra Biosciences Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc.
Simron Singh, MD, MPH
Professor, University of Toronto
Susan Leslie Clinic for Neuroendocrine Tumours
Odette Cancer Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Advisory Committees: Ipsen Biopharmaceuticals Inc, Novartis, Sanofi.
Brian M Slomovitz, MD
Professor, OB-GYN, Florida International University
Director, Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinai Medical Center
Miami, Florida
Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Incyte Corporation, Merck, Novartis, Regeneron Pharmaceuticals Inc, Seagen Inc.
Jonathan Strosberg, MD
Professor
Moffitt Cancer Center and Research Institute
Tampa, Florida
Advisory Committees: Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc; Contracted Research: ITM Isotope Technologies Munich SE, RadioMedix Inc, RayzeBio Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from ADC Therapeutics, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, GSK, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Lilly, Merck, Natera Inc, Novartis, Sanofi, SpringWorks Therapeutics Inc, and Stemline Therapeutics Inc.
Release date: April 2025
Expiration date: April 2026
After completing the post-test, learners may download and review the answers here in order to identify further areas of study.
(WIFI is recommended for best performance):